urokinase-derived peptide a6
Peptideexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2009 (NCT00939809)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- CD44 antigenACTIVATOR
CD44 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- urokinase-derived peptide a6
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02046928 | Phase 2 | Feb 1, 2014 | Ångstrom Pharmaceuticals, University of California, San Diego |
| NCT00939809 | Phase 2 | Jul 1, 2009 | Gynecologic Oncology Group, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ångstrom Pharmaceuticals | For profit | 1 | 1 | 1 | 2014 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2009 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2009 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2014 |
4 organizations
Page 1 / 1